Published in Science on June 24, 2011
Omega-3 vs Very Low Calorie Diet for Liver Size Reduction | NCT03132662
The Role of Microbiome Reprogramming on Liver Fat Accumulation (MILE) | NCT03914495
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology (2014) 4.01
FAT SIGNALS--lipases and lipolysis in lipid metabolism and signaling. Cell Metab (2012) 2.96
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med (2015) 2.86
ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell (2014) 2.31
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature (2014) 2.30
Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol (2015) 2.26
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2012) 2.08
The number of x chromosomes causes sex differences in adiposity in mice. PLoS Genet (2012) 2.02
Diets containing sea cucumber (Isostichopus badionotus) meals are hypocholesterolemic in young rats. PLoS One (2013) 2.01
Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat Med (2012) 1.87
Targeted disruption of G0/G1 switch gene 2 enhances adipose lipolysis, alters hepatic energy balance, and alleviates high-fat diet-induced liver steatosis. Diabetes (2013) 1.87
Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology (2014) 1.81
The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab (2012) 1.79
Activation of aryl hydrocarbon receptor dissociates fatty liver from insulin resistance by inducing fibroblast growth factor 21. Hepatology (2015) 1.78
Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology (2014) 1.73
IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology (2014) 1.69
Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. J Clin Invest (2014) 1.66
The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab (2012) 1.66
Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. J Clin Invest (2014) 1.63
The vagus nerve and the inflammatory reflex--linking immunity and metabolism. Nat Rev Endocrinol (2012) 1.59
Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev (2014) 1.58
Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One (2012) 1.56
Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol (2013) 1.56
Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology (2015) 1.56
Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem (2011) 1.53
Hepatocyte-Specific Depletion of UBXD8 Induces Periportal Steatosis in Mice Fed a High-Fat Diet. PLoS One (2015) 1.47
Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest (2012) 1.45
Nitric oxide regulates mitochondrial fatty acid metabolism through reversible protein S-nitrosylation. Sci Signal (2013) 1.45
High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. PLoS One (2015) 1.44
The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys. PLoS One (2016) 1.43
Bile acid metabolism and signaling. Compr Physiol (2013) 1.42
SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep (2013) 1.41
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Chromatin variation associated with liver metabolism is mediated by transposable elements. Epigenetics Chromatin (2016) 1.38
Dissociating fatty liver and diabetes. Trends Endocrinol Metab (2012) 1.29
Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol (2014) 1.29
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A (2014) 1.24
The role of hepatokines in metabolism. Nat Rev Endocrinol (2013) 1.21
Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol (2011) 1.21
Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol (2012) 1.19
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des (2013) 1.16
Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res (2012) 1.14
Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol (2013) 1.14
Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One (2012) 1.13
Kupffer cells in the liver. Compr Physiol (2013) 1.12
Lipid-mediated regulation of SKN-1/Nrf in response to germ cell absence. Elife (2015) 1.12
Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol (2015) 1.11
CTRP3 attenuates diet-induced hepatic steatosis by regulating triglyceride metabolism. Am J Physiol Gastrointest Liver Physiol (2013) 1.11
Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice. FASEB J (2011) 1.10
Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab (2012) 1.09
Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. J Lipids (2011) 1.09
Cell and tissue engineering for liver disease. Sci Transl Med (2014) 1.08
Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol (2014) 1.08
Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta (2012) 1.08
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res (2015) 1.07
Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol (2012) 1.07
Increased expression of enzymes of triglyceride synthesis is essential for the development of hepatic steatosis. Cell Rep (2013) 1.06
Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol (2014) 1.06
Expanding roles for lipid droplets. Curr Biol (2015) 1.06
PNPLA3 mediates hepatocyte triacylglycerol remodeling. J Lipid Res (2014) 1.05
Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr (2014) 1.05
Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol (2014) 1.05
C/EBP homologous protein-induced macrophage apoptosis protects mice from steatohepatitis. J Biol Chem (2013) 1.05
Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis (2013) 1.05
Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease. PLoS One (2012) 1.04
MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS One (2013) 1.04
Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Int J Mol Sci (2013) 1.04
Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway. Metabolism (2013) 1.03
Spectroscopic Imaging of Deep Tissue through Photoacoustic Detection of Molecular Vibration. J Phys Chem Lett (2013) 1.03
Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet. Biochim Biophys Acta (2014) 1.03
Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol (2014) 1.02
Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol (2012) 1.02
A monocarboxylate transporter required for hepatocyte secretion of ketone bodies during fasting. Genes Dev (2012) 1.02
Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology (2013) 1.02
Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg (2013) 1.01
Saturated fatty acids activate ERK signaling to downregulate hepatic sortilin 1 in obese and diabetic mice. J Lipid Res (2013) 1.01
Deficiency of liver Comparative Gene Identification-58 causes steatohepatitis and fibrosis in mice. J Lipid Res (2013) 1.01
Targeted deletion of C1q/TNF-related protein 9 increases food intake, decreases insulin sensitivity, and promotes hepatic steatosis in mice. Am J Physiol Endocrinol Metab (2014) 1.01
Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. Cell Metab (2016) 1.00
Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol (2015) 1.00
Fatty acid-regulated transcription factors in the liver. Annu Rev Nutr (2013) 1.00
The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease. Cell Cycle (2012) 1.00
Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol (2013) 0.99
Innate immune activation in obesity. Mol Aspects Med (2012) 0.99
Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers. Cell Metab (2014) 0.99
Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes. Best Pract Res Clin Endocrinol Metab (2013) 0.99
Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care (2012) 0.99
Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol (2016) 0.98
Lycopene metabolite, apo-10'-lycopenoic acid, inhibits diethylnitrosamine-initiated, high fat diet-promoted hepatic inflammation and tumorigenesis in mice. Cancer Prev Res (Phila) (2013) 0.98
In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci (2013) 0.97
Sterol regulatory element-binding protein (SREBP) cleavage regulates Golgi-to-endoplasmic reticulum recycling of SREBP cleavage-activating protein (SCAP). J Biol Chem (2014) 0.97
Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One (2012) 0.97
Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease? World J Gastroenterol (2012) 0.96
Disruption of the selenocysteine lyase-mediated selenium recycling pathway leads to metabolic syndrome in mice. Mol Cell Biol (2012) 0.96
Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res (2016) 0.95
Effects of perilipin 2 antisense oligonucleotide treatment on hepatic lipid metabolism and gene expression. Physiol Genomics (2012) 0.95
Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China. Hepatology (2012) 0.95
Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH). Biochim Biophys Acta (2014) 0.95
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest (2002) 21.08
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell (2010) 10.96
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest (2005) 9.09
Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science (2004) 8.58
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab (2004) 8.36
Prevalence of fatty liver in children and adolescents. Pediatrics (2006) 7.00
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med (2010) 6.45
Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem (2004) 5.80
Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology (2010) 5.44
Selective versus total insulin resistance: a pathogenic paradox. Cell Metab (2008) 5.25
Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet (2008) 4.69
Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A (2010) 4.40
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology (2008) 4.28
Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab (2006) 4.02
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
"New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab (2005) 3.86
Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev (2010) 3.60
A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem (2009) 3.41
Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet (2009) 3.24
Heritability of nonalcoholic fatty liver disease. Gastroenterology (2009) 3.17
Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A (2006) 2.88
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res (2009) 2.75
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest (2009) 2.53
Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology (2010) 2.47
Formation of cholesteryl ester-rich particulate lipid during metabolism of chylomicrons. J Clin Invest (1970) 2.40
A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A (2010) 2.34
Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.32
Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis (2009) 2.22
Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res (2008) 2.14
Proteins under new management: lipid droplets deliver. Trends Cell Biol (2007) 2.12
Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology (2010) 2.09
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol (2009) 2.06
Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol (2009) 1.88
CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J Lipid Res (2010) 1.79
Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res (2010) 1.75
Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2008) 1.68
Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med (2000) 1.67
Genetic determinants of hepatic steatosis in man. J Lipid Res (2011) 1.52
Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res (2004) 1.50
Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes (2004) 1.46
The role of cytokines in non-alcoholic fatty liver disease. Dig Dis (2010) 1.41
Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis (2010) 1.40
Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol (2010) 1.33
Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res (2008) 1.28
Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology (2010) 1.22
Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl (2009) 1.10
Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease. J Hepatol (2008) 1.03
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med (2006) 23.83
Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science (2004) 21.65
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet (2007) 13.78
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet (2005) 12.12
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol (2004) 9.43
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab (2004) 8.36
Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A (2006) 8.20
A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet (2006) 7.89
Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med (2010) 6.84
Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem (2002) 5.89
Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest (2008) 5.05
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A (2005) 4.56
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest (2003) 4.42
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology (2014) 4.01
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem (2004) 3.93
PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res (2008) 3.92
Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest (2002) 3.85
Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci (2007) 3.59
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest (2006) 3.54
Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A (2004) 3.54
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem (2007) 3.45
A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem (2009) 3.41
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet (2006) 3.38
Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci U S A (2002) 3.09
LXRs regulate the balance between fat storage and oxidation. Cell Metab (2005) 2.75
Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J Clin Invest (2004) 2.66
Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A (2012) 2.62
ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem (2003) 2.48
Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A (2008) 2.42
A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A (2010) 2.34
Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. Hum Mol Genet (2010) 2.19
African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol (2004) 2.16
Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes (2010) 2.10
Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology (2010) 2.09
Schoenheimer effect explained--feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. J Clin Invest (2005) 2.03
Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest (2002) 2.02
Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res (2008) 1.98
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem (2007) 1.97
Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci U S A (2013) 1.96
Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab (2009) 1.95
WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics (2006) 1.95
No association between plasma levels of plant sterols and atherosclerosis in mice and men. Arterioscler Thromb Vasc Biol (2004) 1.93
Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res (2008) 1.91
ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2. J Biol Chem (2002) 1.89
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A (2008) 1.86
The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab (2012) 1.79
Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab (2009) 1.79
Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem (2006) 1.72
Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet (2002) 1.69
Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem (2003) 1.67
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature (2007) 1.66
Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem (2009) 1.65
Genetic variation in ANGPTL4 provides insights into protein processing and function. J Biol Chem (2009) 1.64
Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. J Biol Chem (2002) 1.63
Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. J Lipid Res (2008) 1.61
Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem (2004) 1.57
Normal sorting but defective endocytosis of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemia. J Biol Chem (2003) 1.56
Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem (2011) 1.53
Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease. Hepatology (2005) 1.48
Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest (2012) 1.45
Dual roles for cholesterol in mammalian cells. Proc Natl Acad Sci U S A (2005) 1.43
Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J Lipid Res (2002) 1.38
Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes. Hum Mol Genet (2008) 1.37
ATP-citrate lyase deficiency in the mouse. J Biol Chem (2003) 1.35
Compensatory increase in fatty acid synthesis in adipose tissue of mice with conditional deficiency of SCAP in liver. Cell Metab (2005) 1.34
Molecular mechanisms of autosomal recessive hypercholesterolemia. Hum Mol Genet (2002) 1.33
Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression. PLoS One (2011) 1.27
The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem (2005) 1.25
Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J Lipid Res (2003) 1.23
The Xbp1s/GalE axis links ER stress to postprandial hepatic metabolism. J Clin Invest (2012) 1.23
Disruption of cholesterol homeostasis by plant sterols. J Clin Invest (2004) 1.22
Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia. J Clin Invest (2007) 1.22
Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 provides a tertiary level of regulation of fatty acid synthesis. Proc Natl Acad Sci U S A (2010) 1.21
High-level expression of ABCG5 and ABCG8 attenuates diet-induced hypercholesterolemia and atherosclerosis in Ldlr-/- mice. J Lipid Res (2004) 1.21
Missense mutations in ABCG5 and ABCG8 disrupt heterodimerization and trafficking. J Biol Chem (2004) 1.20
Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res (2012) 1.18
Crystal structure of Spot 14, a modulator of fatty acid synthesis. Proc Natl Acad Sci U S A (2010) 1.15
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest (2012) 1.14
The modular adaptor protein ARH is required for low density lipoprotein (LDL) binding and internalization but not for LDL receptor clustering in coated pits. J Biol Chem (2004) 1.10
Molecular mechanisms of autosomal recessive hypercholesterolemia. Curr Opin Lipidol (2003) 1.10
Genetics. Simple genetics for a complex disease. Science (2013) 1.10
A phylogenetic survey of biliary lipids in vertebrates. J Lipid Res (2005) 1.08
ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile. J Lipid Res (2005) 1.06
Deletion of GPIHBP1 causing severe chylomicronemia. J Inherit Metab Dis (2011) 1.06
Sterol transfer by ABCG5 and ABCG8: in vitro assay and reconstitution. J Biol Chem (2006) 1.03
Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res (2010) 1.03
Human 1-acylglycerol-3-phosphate O-acyltransferase isoforms 1 and 2: biochemical characterization and inability to rescue hepatic steatosis in Agpat2(-/-) gene lipodystrophic mice. J Biol Chem (2011) 1.01
Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab (2009) 0.99
Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8. J Lipid Res (2005) 0.98